Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally…
FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominanceFYARRO launch planned for Q1 2022; Investor call to be held today…